Dechra Pharmaceuticals PLC Logo

Dechra Pharmaceuticals PLC

ISIN: GB0009633180 | Ticker: DPH | LEI: 213800J4UVB5OWG8VX82
Sector: Health CareSub-Industry: Pharmaceuticals
Country: United Kingdom

About Dechra Pharmaceuticals PLC

Company Description

Dechra Pharmaceuticals PLC is a global veterinary pharmaceutical company that specializes in developing and marketing high-quality products for the treatment of animals. Founded in 1997, the company has grown to become a major player in the animal health industry, with a presence in over 45 countries around the world.

Dechra Pharmaceuticals PLC is committed to improving the lives of animals through its innovative and effective products. The company's portfolio includes a wide range of products, including pharmaceuticals, vaccines, and nutritional supplements, for a variety of species, including dogs, cats, horses, and farm animals.

Year founded


Served area





24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, CW9 7UA Northwich – United Kingdom

Financial statements

Download as Excel
Line item in (gbp) 01.07.2020 01.07.2021 01.07.2022
Assets N/A 1,214,100,000.00 1,293,300,000.00
Noncurrent Assets N/A 821,900,000.00 848,900,000.00
Property Plant And Equipment N/A 87,000,000.00 100,300,000.00
Investments In Associates Accounted For Using Equity Method N/A 17,100,000.00 15,800,000.00
Deferred Tax Assets N/A 2,000,000.00 2,300,000.00
Current Assets N/A 392,200,000.00 444,400,000.00
Inventories N/A 149,500,000.00 175,700,000.00
Trade And Other Current Receivables N/A 106,700,000.00 136,800,000.00
Current Tax Assets Current N/A 17,600,000.00 11,000,000.00
Cash and cash equivalents 227,400,000.00 118,400,000.00 120,900,000.00
Equity 637,500,000.00 632,900,000.00 666,800,000.00
Issued Capital N/A 1,100,000.00 1,100,000.00
Retained Earnings N/A 147,700,000.00 164,000,000.00
Share Premium N/A 411,600,000.00 413,900,000.00
Merger Reserve N/A 84,400,000.00 84,400,000.00
Liabilities N/A 581,200,000.00 626,500,000.00
Noncurrent Liabilities N/A 425,400,000.00 467,800,000.00
Noncurrent Provisions N/A 3,500,000.00 2,200,000.00
Deferred Tax Liabilities N/A 48,800,000.00 35,800,000.00
Current Liabilities N/A 155,800,000.00 158,700,000.00
Trade And Other Current Payables N/A 113,500,000.00 136,800,000.00
Current Tax Liabilities Current N/A 16,600,000.00 12,200,000.00
Line item in (gbp) 01.07.2020/
Revenue 608,000,000.00 681,800,000.00
Profit Loss From Operating Activities 84,000,000.00 95,500,000.00
Finance Income 3,800,000.00 5,700,000.00
Finance Costs 12,700,000.00 22,300,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method -1,100,000.00 -1,300,000.00
Profit Loss Before Tax 74,000,000.00 77,600,000.00
Income Tax Expense Continuing Operations 18,500,000.00 19,400,000.00
Profit (loss) 55,500,000.00 58,200,000.00
Line item in (gbp) 01.07.2020 01.07.2021 01.07.2022
Profit (loss) N/A 55,500,000.00 58,200,000.00
Adjustments For Decrease Increase In Inventories N/A -36,600,000.00 -19,300,000.00
Adjustments For Sharebased Payments N/A 2,800,000.00 3,300,000.00
Cash Flows From Used In Operations N/A 141,200,000.00 163,300,000.00
Cash Flows From Used In Operating Activities N/A 89,100,000.00 122,900,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 900,000.00 800,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 200,000.00 0.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 18,900,000.00 20,300,000.00
Proceeds From Sales Of Intangible Assets Classified As Investing Activities N/A 200,000.00 0.00
Interest Received Classified As Investing Activities N/A 0.00 100,000.00
Cash Flows From Used In Investing Activities N/A -136,100,000.00 -78,300,000.00
Proceeds From Issuing Shares N/A 2,300,000.00 2,300,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 15,900,000.00 0.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 3,600,000.00 3,600,000.00
Dividends Paid Classified As Financing Activities N/A 37,900,000.00 44,800,000.00
Cash Flows From Used In Financing Activities N/A -55,100,000.00 -46,100,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -102,100,000.00 -1,500,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -6,900,000.00 4,000,000.00
Cash and cash equivalents 227,400,000.00 118,400,000.00 120,900,000.00

Please note that some sums might not add up.

Filings & Publications


Consolidated Report
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Short Interest

Current short interest

Position Holder Short Interest in Percent Date
Qube Research & Technologies Limited 1.07% 10.08.23
Qube Research & Technologies Limited 1.32% 21.09.23
Qube Research & Technologies Limited 1.36% 24.08.23
Qube Research & Technologies Limited 1.28% 07.09.23
Total 5.03%

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

London Stock Exchange

Stock Index

FTSE 250

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.